Last reviewed · How we verify
GSK Biologicals' trivalent influenza vaccine
GSK Biologicals' trivalent influenza vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | GSK Biologicals' trivalent influenza vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pain
- Fatigue
- Headache
- Myalgia
- Nausea
- Arthralgia
- Shivering
- Redness
- Swellling
Key clinical trials
- Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years (PHASE3)
- A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity (NA)
- Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab
- Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years (PHASE3)
- Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older (PHASE3)
- Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old (PHASE4)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals' trivalent influenza vaccine CI brief — competitive landscape report
- GSK Biologicals' trivalent influenza vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Biologicals' trivalent influenza vaccine
What is GSK Biologicals' trivalent influenza vaccine?
GSK Biologicals' trivalent influenza vaccine is a Biologic drug developed by GlaxoSmithKline.
Who makes GSK Biologicals' trivalent influenza vaccine?
GSK Biologicals' trivalent influenza vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK Biologicals' trivalent influenza vaccine in?
GSK Biologicals' trivalent influenza vaccine is in Phase 1.
What are the side effects of GSK Biologicals' trivalent influenza vaccine?
Common side effects of GSK Biologicals' trivalent influenza vaccine include Pain, Fatigue, Headache, Myalgia, Nausea, Arthralgia.